860799 | CP-LC-0729
2-hexyldecyl 3-((4-((2-(dimethylamino)ethyl)amino)-3-(2-hexyldecanamido)-4-oxobutyl)thio)propanoate
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
CP-LC-0729
2-hexyldecyl 3-((4-((2-(dimethylamino)ethyl)amino)-3-(2-hexyldecanamido)-4-oxobutyl)thio)propanoate
Manufactured and Distributed under License from Certest Biotec S.L
In vivo studies carried out in mice show that lipid nanoparticle (LNP) formulations using ionizable lipid CP-LC-0729 exhibit increased mRNA expression, similar antibody and Th1 immune responses, and favorable safety profiles compared to industry-leading formulations. Like other industry-leading formulations, LNPs formulated with CP-LC-0729 have shown a primary biodistribution in the liver.
Lyophilized LNPs formulated with CP-LC-0729 stored in refrigerated conditions (4°C) proved to have much improved stability profiles compared to industry-leading liquid formulations stored at 4°C. After twelve months of storage, when comparing antibody response of lyophilized LNPs formulated with CP-LC-0729 stored at 4°C to industry-leading liquid LNP formulations stored at -80°C, the antibody responses were similar.
pKa in formulation = 6.78 (measured by TNS)
| C43H85N3O4S |
Powered by Bioz
